Show
Sort by
-
Long-term safety with everolimus-based regimen in de novo liver transplant recipients: 4-year results from the extension of H2304 study
-
Long-term safety with everolimus-based regimen in de novo liver transplant recipients: 4-year results from the extension of H2304 study
-
Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial